Direction médicale, EFS Siège, Saint Denis, France.
Direction des maladies infectieuses, Santé publique France, Saint Maurice, France.
Euro Surveill. 2024 Aug;29(32). doi: 10.2807/1560-7917.ES.2024.29.32.2400036.
BackgroundSyphilis in blood donors (BD) has increased in many countries.AimWe aimed to describe trends in syphilis seroposivity in BD in France, to identify risk factors and assess if a non-treponemic test (NTT) could define BD having recovered from syphilis for more than 1 year.MethodsThe analysis covered the period 2007 to 2022 and 45,875,939 donations. Of the 474 BD syphilis-positive in 2022, 429 underwent additional investigations with an NTT. History of syphilis was obtained at the post-donation interview or based on serology results for repeat donors.ResultsUntil 2021, positivity rates remained stable (mean: 1.18/10,000 donations, range: 1.01-1.38). An increased rate was observed in 2022 (1.74/10,000; p = 0.02). Over the whole study period, prevalence was 2.2 times higher in male than in female BD (4.1 times higher in 2022). The proportion of males with an identified risk factor who have sex with men increased from 16.7% in 2007 to 64.9% in 2022. Based on NTT, 79 (18%) of the donors who were seropositive in 2022 were classified as having been infected in the previous year. History of syphilis was available for 30 of them. All had an infection within the previous 3 years. Among seven donors with a syphilis < 12 months before testing, one had an NTT titre ≥ 8, three a titre between 1 and 4, three were negative.ConclusionSyphilis seropositivity increased considerably in BDs in 2022, mostly in males, notably MSM. Available data did not allow appropriate evaluation of the NTT to distinguish recent from past infection.
在许多国家,献血者中的梅毒(syphilis)有所增加。
我们旨在描述法国献血者梅毒血清阳性率的趋势,确定相关风险因素,并评估非梅毒螺旋体试验(non-treponemic test,NTT)是否可用于定义梅毒感染已超过 1 年的献血者。
该分析涵盖了 2007 年至 2022 年期间的 45875939 次献血。2022 年发现 474 例梅毒阳性的献血者,其中 429 例接受了 NTT 进一步检查。梅毒史通过献血后访谈或基于重复献血者的血清学结果获得。
在 2021 年之前,阳性率保持稳定(平均值:1.18/10000 次献血,范围:1.01-1.38)。2022 年观察到阳性率增加(1.74/10000;p=0.02)。在整个研究期间,男性献血者的梅毒患病率是女性的 2.2 倍(2022 年则为 4.1 倍)。在有明确风险因素的男性中,男男性行为者的比例从 2007 年的 16.7%增加到 2022 年的 64.9%。基于 NTT,2022 年检测呈阳性的 79 例献血者被归类为在去年感染。其中 30 例有梅毒史。他们均在过去 3 年内感染。在 7 例检测前 12 个月内梅毒<12 个月的献血者中,1 例 NTT 滴度≥8,3 例滴度在 1 至 4 之间,3 例滴度为阴性。
2022 年,献血者梅毒血清阳性率大幅增加,主要发生在男性,尤其是男男性行为者中。现有数据无法适当评估 NTT 以区分近期和既往感染。